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ABSTRACT
The pharmacokinetics, urinary excretion and dosage regimen of cefotaxime after its single intravenous 
administration (10 mg.kg-1) was investigated in hepatic-dysfunctioned buffalo calves. Hepatic-dysfunction was 
induced by intramuscular administration of paracetamol (250 mg.kg-1 body weight on day 1, followed by two 
subsequent doses of 50 mg.kg-1 body weight on day 3 and 5). At 1 min, the concentration of cefotaxime in plasma 
was 69.6 ± 1.54 µg.ml-1 which rapidly declined to 11.5 ± 0.41 µg.ml-1 at 15 min. The drug was detected upto 5 
h. The elimination half-life and volume of distribution were 0.94 ± 0.02 h and 1.48 ± 0.07 L.kg-1, respectively. 
The distribution half-life and AUC were 0.055 ± 0.003 h and 9.20 ± 0.47 µg.ml-1.h, respectively. The total 
body clearance (ClB) and tissue/plasma (T/C) ratio were 1.1 ± 0.06 L.kg
-1.h-1 and 11.5 ± 0.89, respectively. 
Approximately 3% of the total administered dose of cefotaxime was recovered in urine within 24 h after 
administration. Cefotaxime was bound to plasma proteins of hepatic-dysfunctioned buffalo calves to the extent 
of 31-35.2%. A satisfactory intravenous dosage regimen for cefotaxime in hepatic-dysfunctioned buffalo calves 
would be 13 mg/kg body weight at 6 h intervals. 
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Introduction
Cefotaxime, a semisynthetic bactericidal cephalosporin, is effective against a 
wide variety of Gram-positive and Gram-negative microorganisms (NEU et al., 1979). 
Pharmacokinetics of chemotherapeutic agents are markedly altered in disease conditions 
(LESAR and ZASKE 1984; HARY et al., 1989; TOTH et al., 1991; SINGH et al., 1998; 
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CHAUDHARY et al., 1999), hence the dosage regimen obtained in healthy subjects cannot 
be extrapolated in clinical cases to treat diseased animals. Since liver is the main site of 
biotransformation and elimination of drugs, hepatic dysfunction certainly poses a potential 
therapeutic problem by altering the disposition kinetics of antimicrobial drugs.
The purpose of this study was to determine the disposition kinetic variables of 
cefotaxime and its urinary excretion in hepatic-dysfunctioned buffalo calves following 
intravenous administration. From the disposition kinetic data, recommendations were made 
for optimal dosage regimens of cefotaxime in hepatic-dysfunctioned buffalo calves. 
Materials and methods
Animals and treatment. Five healthy male buffalo calves ranging between 1 and 1.5 
years of age with an average weight of 65.4 kg were used. The animals were housed 
in an animal shed with concrete floor and adequate ventilation. A constant supply of 
water was maintained in the shed. All the animals were acclimatized in the animal shed 
under uniform conditions and were maintained on green fodder and wheat straw and 
water ad libitum. Hepatic dysfunction was induced by intramuscular administration of 
paracetamol. The dosage schedule of paracetamol was 250 mg.kg-1 body weight on day 
1, followed by 2 subsequent doses of 50 mg.kg-1 body weight on day 3 and 5. The extent 
of hepatic dysfunction was determined by regular estimation of plasma levels of aspartate 
aminotransferase (AST), alkaline phosphatase (ALP) and cholesterol at every 24 h, intervals. 
On the basis of above biochemical parameters, day 6 after administration of first dose 
of paracetamol, was taken as the time of full onset of hepatic dysfunction. Once hepatic 
dysfunction was set, cefotaxime was administered by single intravenous injection into the 
jugular vein at 10 mg.kg-1 body weight, in a 10% solution with sterilized distilled water. 
Experimental and assay procedures. Before the start of experiment, the animals were 
kept in metabolic stalls of standard size. The stalls were prepared in such a way that all 
the urine voided by animals could be collected over the chosen time intervals without any 
contamination or spillage. Following the administration of cefotaxime, blood samples (5 
ml) were withdrawn from the contralateral jugular vein into heparinized glass test tubes 
before administration and at 1, 2.5, 5, 7.5, 10, 15, 30, 45, 60, 90 min and 2, 3, 4 and 5 h 
after administration of the drug. Plasma was collected after centrifugation at 2000 g for 15 
min at room temperature and kept at -20 °C until analysis, usually the next day. The urine 
samples were collected at 4, 8, 12, 16, 20 and 24 h after drug administration. The volume 
of urine was measured and approximately 8-10 ml was frozen for analysis. 
Analytical procedure. The plasma activities of asparate aminotransferase and alkaline 
phosphatase were determined by the method of WOOTTON (1964). Plasma level of 
cholesterol was determined by procedure of WYBENGA et al. (1970). The concentration of 
cefotaxime in the plasma and urine were estimated by employing the microbiological assay 
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technique (ARRET et al., 1971) using Escherichia coli (ATCC 25922) as the test organism. 
This method detected both parent and active metabolities of cefotaxime. The assay could 
detect a minimum of 0.1 µg.ml-1 of cefotaxime. The standard curve of cefotaxime in buffalo 
calf plasma was linear between 0.1 to 0.6 µg.ml-1. The value of correlation coefficient (r) 
and coefficient of variation were 0.99 and 4.8%, respectively. Kinetic parameters were 
determined according to the method of computed least squares (GIBALDI and PERRIER, 
1982). The in vitro plasma protein binding was determined by an equilibrium dialysis 
technique at plasma concentration of 2, 5, 10, 25, 50 and 100 µg.ml-1. 
Results 
The plasma activities of AST, ALP and cholesterol level after paracetamol 
administration are presented in Table 1. 
Table 1. Effect of repeated administration of paracetamol* employed to induce hepatic-
dysfunction, on plasma activity of aspartate aminotransferase, alkaline phosphatase and plasma 





(n mol pyruvate 
formed.min-1.ml-1)
Alkaline phosphatase 




0 32.5 ± 1.06 (100) 21.3 ± 0.88 (100) 59.9 ± 1.39 (100)
1 50.6 ± 1.70 (156)** 31.0 ± 0.54 (146) ** 64.2 ± 1.36 (107) **
2 54.0 ± 3.34 (166) ** 70.3 ± 4.71 (330) ** 67.2 ± 0.76 (112) **
3 61.7 ± 2.96 (190) ** 77.5 ± 2.27 (364) ** 65.5 ± 1.81 (109) **
4 70.3 ± 2.37 (216) ** 66.6 ± 2.21 (313) ** 70.0 ± 0.63 (117) **
5 76.5 ± 2.56 (235) ** 54.8 ± 4.17 (257) ** 72.3 ± 1.38 (121) **
6 81.8 ± 1.09 (252) ** 76.0 ± 2.46 (357) ** 76.5 ± 1.03 (128) **
7 78.6 ± 1.39 (242) ** 75.9 ± 3.44 (356) ** 74.9 ± 2.26 (125) **
8 74.1 ± 1.27 (228) ** 68.7 ± 4.49 (323) ** 75.5 ± 2.12 (126) **
9 65.7 ± 2.76 (202) ** 64.9 ± 3.17 (305) ** 76.4 ± 1.62 (128) **
10 57.7 ± 2.94 (178) ** 54.3 ± 4.22 (255) ** 75.7 ± 1.50 (126) **
12 51.9 ± 1.59 (160) ** 46.5 ± 2.22 (218) ** 75.8 ± 1.49 (126) **
14 45.9 ± 3.07 (141) ** 37.6 ± 2.21 (176) ** 75.8 ± 1.49 (126) **
The values given are mean ± SE of results obtained from 5 animals. Figures in parentheses indicate 
the percentage of corresponding control (0 day) values taking the values of 0 day as 100 per cent. 
*The dosage schedule of paracetamol was 250 mg.kg-1 i/m on day 1; followed by 50 mg.kg-1 i/m 
on day 3; followed by 50 mg.kg-1 i/m on day 5. **Significantly (P<0.05) different as compared to 
corresponding value of 0 day. 
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The mean plasma concentrations of cefotaxime as a function of time in hepatic-
dysfunctioned buffalo calves were plotted on a semilogarithmic scale (Fig. 1). At 1 min 
the mean plasma concentration of cefotaxime was 69.6 ± 1.54 µg.ml-1, which rapidly 
declined to 11.5 ± 0.41 µg.ml-1 at 15 min. Thereafter it gradually disappeared from plasma 
and at 5 h only a concentration of 0.04 ± 0.02 µg.ml-1 of cefotaxime was detected. Table 2 
presents the calculated values of the pharmacokinetic parameters in hepatic-dysfunction 
buffalow calves. Table 3 shows the urinary excretion of cefotaxime in hepatic-dysfunctioned 
buffalo calves. 
Table 2. Pharmacokinetic parameters of cefotaxime in buffalo calves (n = 5) in which hepatic-
dysfunction was induced by repeated administration of paracetamol and subsequently cefotaxime 
was administered in a single intravenous dose of 10 mg.kg-1 body weight
Parameter Unit Mean ± SE
Cp° µg.ml
-1 84.1 ± 2.30
A µg.ml-1 82.1 ± 2.48
B µg.ml-1 2.04 ± 0.25
α h-1 12.8 ± 0.76
β h-1 0.742 ± 0.017
t1⁄2α h 0.055 ± 0.003
t1⁄2β h 0.94 ± 0.02
K12 h
-1 3.24 ± 0.18
K21 h
-1 1.03 ± 0.04
K12/K21 Ratio 3.15 ± 0.12
K10 h
-1 9.29 ± 0.71
AUC µg.ml-1.h 9.20 ± 0.47
Vc L.kg
-1 0.12 ± 0.003
Vd(area) L.kg
-1 1.48 ± 0.07
ClB L.kg
-1.h-1 1.1 ± 0.06
T/C Ratio 11.5 ± 0.89
Td h 5.28 ± 0.12
Cp° = plasma drug concentration at time zero after intravenous dose; A and B are zero intercepts of distribution 
and elimination phase, respectively; α and β are distribution and elimination rate constants, respectively, t1⁄2α 
= distribution half-life; t1⁄2β = elimination half-life; K12 and K21 are rate constants of drug transfer from central 
to peripheral and from peripheral to central compartments, respectively; K10 = rate constant for elimination of 
drug from central compartment; AUC = area under the plasma drug concentration – time curve; Vc = Volume of 
central compartment; Vd(area) = apparent volume of distribution, ClB = total plasma clearance; T/C = ratio of drug 
concentration between peripheral and central compartment; td = duration of therapeutic plasma concentration.
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Fig. 1. A semilogarithmic plot of plasma levels of cefotaxime after a single intravenous dose of 
10 mg.kg-1 body weight in hepatic-dysfunctioned buffalo calves. Values given are mean ± SE of 
5 animals. Data were analysed according to two compartment open model. The calculated points 
(O) of the distribution phase are obtained by feathering techniques. 
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Taking 4, 6 and 8 h as convenient dosage intervals (τ), with a minimum therapeutic 
concentration [Cp(min)
∞] of 0.05, 0.1, 0.2 and 0.4 µg.ml-1 and using the values of β and 
Vd(area) of table 2, the dosage regimen for cefotaxime in hepatic-dysfunctioned buffalo 
calves were computed and are presented in Table 4.
Table 3. Urinary excretion of cefotaxime in buffalo calves in which hepatic-dysfunction was 
induced by repeated administration of paracetamol and subsequently cefotaxime was administered 
in a single intravenous dose of 10 mg/kg body weight 
Time interval (h) Cumulative percent of total dose excreted
0-4 0.58 ± 0.28
0-8 2.85 ± 0.22
0-12 3.01 ± 0.28
0-16 3.12 ± 0.25
0-20 3.14 ± 0.26
0-24 3.15 ± 0.26
The values given are mean ± SE of the results obtained from 4-5 animals. 
Table 4. Dosage regimen of cefotaxime in hepatic-dysfunctioned buffalo calves, at various dosage 
intervals for microorganisms of different susceptibility
MTC Dosage interval (h)
(µg/ml) 4 6 8
0.05 1.44 (1.36) 6.35 (6.30) 28.0 (27.9)
0.1 2.88 (2.73) 12.7 (12.6) 56.0 (55.9)
0.2 5.76 (5.46) 25.4 (25.1) 112.0 (111.7)
0.4 11.5 (10.9) 50.8 (50.2) 224.0 (223.4)
Values are expressed as mg/kg body weight. Values of maintenance doses are given in parentheses. 
MTC- Minimum therapeutic plasma concentration
Discussion
Hepatic-dysfunction was produced by repeated administration of paracetamol (250 
mg.kg-1 body weight im on day 1, followed by 50 mg.kg-1 b.wt on day 3 and 5). Paracetamol 
was also reported to produce hepatic injury in man (PROUDFOOT and WRIGHT, 1970), 
experimental animals (MITCHELL et al., 1973), sheep (BHAUMIC et al., 1995) and buffalo 
calves (KUMAR, 1999). 
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The plasma activities of AST, ALP and cholesterol level after paracetamol administration 
remained significantly high upto 14th day. The elevation in AST activity may be attributed 
to its release from ruptured hepatocytes or escape though membranes because of altered 
permeability, which is caused by hepatotoxic effects of paracetamol. The increase in ALP 
activity may be due to production in response to hepatic necrosis and injury to intrahepatic 
bile canaliculi. Hypercholesterolaemia may be due to utilization of volatile fatty acids by 
damaged liver for glycogenesis which entered in the circulation. The decreased metabolism/ 
excretion of cholesterol by liver may be another contributing factor. 
Evaluation of the mean plasma concentrations of cefotaxime as a function of time in 
hepatic-dysfunctioned buffalo calves revealed biphasic decline of plasma drug concentration 
and were fitted in 2-compartment open model. The disposition of cefotaxime was adequately 
described by a bi-exponential equation, Cp = Ae-αt+Be-βt. Cefotaxime, after intravenous 
administration has also been reported to follow two-compartment open model in man 
(KEMMERICH et al., 1983), dogs (GUERRINI et al., 1986), goats (ATEF et al., 1990) and healthy 
buffalo calves (SHARMA, 2000). 
The high value of rate constant α (12.8 ± 0.76 h-1) and volume of distribution (1.48 ± 
0.07 L.kg-1) indicated that cefotaxime is rapidly and extensively distributed into various 
body fluids and tissues. The elimination half-life of cefotaxime in hepatic-dysfunctioned 
buffalo calves was 0.94 ± 0.02 h which was considerably lesser than its half-life in healthy 
cow calves and buffalo calves. The elimination half-life of cefotaxime in healthy cow calves 
(SHARMA et al., 1995) and buffalo calves (SHARMA, 2000) have been reported to be 3.48 
± 1.17 h and 1.19 ± 0.05 h, respectively. In accordance to the result, the value of the total 
body clearance of cefotaxime in hepatic-dysfunctioned buffalo calves (1.1 ± 0.06 L.kg-
1.h-1) was higher as compared to healthy crossbred calves and buffalo calves. The values 
of ClB in healthy crossbred calves (SHARMA et al., 1995) and buffalo calves (SHARMA, 
2000) have been calculated to be 0.81 ± 0.10 and 0.68 ± 0.04 L.kg.-1.h-1, respectively. The 
results of the present study revealed marked differences in kinetic behaviour of cefotaxime 
as compared to healthy buffalo calves. 
The precise mechanisms for enhanced drug clearance in hepatic-dysfunctioned patients 
remain to be elucidated. Recently, it has been reported that during hepatic dysfunction, 
the phase I mixed function oxidases are selectively affected i.e. cytochome P450 (CYP), 
1A2 and CYP2CB have enhanced activity while other CYP isoforms such as CYP2C9 
and CYP3A4 remain unaffected. Increased activities of phase II enzymes i.e glucuronyl 
transferase, acetyl transferase and sulfotransferase have also been demonstrated. So the 
increased hepatic clearance of drugs during hepatic dysfunction may be the consequence 
of disease specific changes in both enzyme activity and/or drug transport within the liver 
(REY et al., 1998). 
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At the end of 24 h, the urinary excretion was 3% of total administered dose, which 
was similar to that of healthy buffalo calves (SHARMA, 2000). In healthy crossbred calves, 
following a single intravenous administration of cefotaxime (10 mg.kg-1) approximately 
4.5% of drug was recovered in urine within 12 h (SHARMA et al., 1995). TOTH et al. (1991) 
have also reported that the fraction of the administered dose of ceftriaxone excreted in urine 
of liver transplant recipients did not differ markedly from that of normal subjects. 
The extent of binding of cefotaxime to plasma protein of hepatic-dysfunctioned buffalo 
calves was 32.5 ± 2.07 per cent. Similar to this, cefotaxime was reported to bind plasma 
proteins of human (NEU, 1982) and crossbred calves (SHARMA and SRIVASTAVA 1994) 
to the extent of 36-40 and 30.2 per cent, respectively. 
The method of detection used in this study did not distinguish between the parent drug 
and its metabolites. So the plasma levels of the drug are actually the efficacies of both 
parent drug and its active metabolites. So the possibility of altered metabolism in diseased 
liver is there. But ultimate objective of the present study was to determine a satisfactory 
dosage regimen of cefotaxime in hepatic-dysfunctioned buffalo calves. It is not axiomatic 
to compute the dosage regimen of cefotaxime to be used effectively in clinical practice, 
without having first conducted a detailed pharmacokinetic study. Thus the appropriate 
dosage schedule of cefotaxime on the basis of its pharmacokinetic data was calculated 





The priming dose (D) is obtained by omitting –1 from the above equation. With a 
minimum therapeutic plasma concentration (MTC) of cefotaxime as 0.1 µg.ml-1, which 
has been shown to be most effective against the majority of sensitive Gram-positive and 
Gram-negative pathogens (BARRIERE and FLAHERTY, 1984), in practice the suitable dosage 
schedule of cefotaxime in hepatic-dysfunctioned buffalo calves would be 13 mg/kg to be 
repeated at 6 h intervals. 
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SAŽETAK
Istražena je farmakokinetika, izlučivanje mokraćom i doziranje cefotaksima u bivolske teladi s poremećenom 
jetrenom funkcijom nakon njegove jednokratne intravenske primjene  u količini 10 mg.kg-1. Jetrena disfunkcija 
bila je prouzročena intramuskularnom primjenom paracetamola u količini 250 mg.kg-1 tjelesne mase  prvog dana, 
a zatim po 50 mg.kg-1 tjelesne mase  trećega i petoga dana. Koncentracija cefotaksima u plazmi iznosila je u prvoj 
minuti 69,6 ± 1,54 μg.ml-1, a u petnaestoj minuti smanjila se na 11,5 ± 0,41 μg.ml-1.  Lijek se mogao dokazati 
pet sati nakon primjene. Poluvrijeme njegova izlučivanja iznosilo je 0.94 ± 0,02 h, a volumen distribucije 1,48 
± 0,07 L.kg-1. Poluvrijeme distribucije bilo je 0,055 ± 0,003 h, a AUC 9,20 ± 0,47 μg.ml-1.h. Ukupni tjelesni 
klirens iznosio je 1,1 ± 0,06 L.kg-1.h., dok je odnos tkivo/plazma bio 11,5 ± 0,89. Oko 3% ukupno primijenjene 
doze cefotaksima dokazano je u mokraći unutar 24 sata  nakon davanja. Cefotaksim je bio vezan od 31 do 35,2% 
na bjelančevine plazme  u teladi s poremećenom jetrenom funkcijom. Zadovoljavajuće doziranje cefotaksima u 
bivolske teladi s poremećenom jetrenom funkcijom bilo bi 13 mg/kg tjelesne mase  u razmaku od 6 sati.
Ključne riječi: bivolska telad, cefotaksim, doziranje, jetrena disfunkcija, farmakokinetika
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